Clinical Trial Update: A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Severe to Very Severe Alopecia Areata in Adult Patients (Rezolve AA) [Phase 2]

View source ↗

Summary

A Phase 2b clinical trial (Rezolve AA) is evaluating Rezpegaldesleukin (Rezpeg) for treating severe to very severe alopecia areata in adult patients; the study …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alopecia Areata

Drugs mentioned

• Rezpegaldesleukin (Rezpeg) (Rezpegaldesleukin)

Snippet

Sponsor: Nektar Therapeutics | Conditions: Alopecia Areata | Phase 2 | Status: ACTIVE_NOT_RECRUITING